ArticleThe Lancet regional health. Southeast Asia2025
Comprehensive primary health care for cost-effective scale-up of depression screening in India: an economic modelling study.
Article in The Lancet regional health. Southeast Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Is universal depression screening cost-effective across all Indian states? Addressing parameter uncertainty: author's reply.The Lancet regional health. Southeast Asia · 2026Article
- Is universal depression screening cost-effective across all Indian states? Addressing parameter uncertainty.The Lancet regional health. Southeast Asia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Government of India envisions integrating population-based depression screening within the framework of comprehensive primary health care. This study assesses the economic impact and cost-utility of implementing universal depression screening for different age groups (≥30 years and ≥20 years) compared to the current practice of opportunistic diagnosis and management of symptomatic patients. Methods: A hybrid model comprising of a decision tree and Markov model was developed for economic evaluation. The input parameters were acquired through comprehensive literature search, stakeholder consultations, analysis of the data from National Mental Health Survey, and the National Sample Survey, besides primary data collected from 259 patients for quality of life. The analysis was performed from both abridged societal (consideration of direct costs) and societal perspective (consideration of direct as well as indirect costs). In line with Indian economic evaluation standards, a screening strategy was deemed cost-effective if its incremental cost-utility ratio (ICUR) was below the per capita gross domestic product (GDP) threshold of ₹1,71,498 ($2182). Findings: The gain in QALYs per person from universal screening ranged from 0·0273 (0·0265-0·0281) to 0·0295 (0·0287-0·0303), depending on the target age group. The program is expected to generate net savings of ₹291 billion ($3·7 billion) to ₹482 billion ($6·1 billion), equivalent to 0·19% to 0·32% of GDP. Furthermore, the ICURs were below the threshold, with ≥20 years aged cohort screening (₹43,995, $620) being more cost-effective than the screening in ≥30 years aged population (₹48,746, $560) from the abridged societal perspective. However, the program ceases to yield positive net health benefits if the sensitivity of the PHQ-2 decreases to 26%, or if the combined sensitivity of the sequential PHQ-2 and PHQ-9 approach falls below 35%. The intervention is likely to result in cost savings if at least 60% of patients seeking treatment after screening use public health facilities. Interpretation: Integrating depression screening and management into the government primary healthcare system provides substantial public health and economic benefits, supporting the case for a PHC-oriented health system. Expanding coverage to individuals aged 20 years and above, along with ensuring high diagnostic accuracy through quality training and supportive supervision, will be key to sustaining and maximizing the programme's impact. Funding: The study was supported by funding from the Department of Health Research, Ministry of Health and Family Welfare, Government of India.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.